Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
ROSETTA CRC-203 trial: what clinicians have said so far
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- NCT07221357 ↗
- Recruiting
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ROSETTA CRC-203 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ROSETTA CRC-203 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions
- Pumitamig; FOLFOX; FOLFIRI; Bevacizumab; CAPOX
- Arms
- Arm A1 · Experimental
- Arm A2 · Experimental
- Arm B · Other
- Arm C · Experimental
- Arm D · Other
- Enrollment
- 990 (estimated)
- Primary outcomes
- Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
- Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)
- Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb with BioNTech SE
- Start
- Dec 31, 2025
- Primary completion
- Feb 2, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07221357 · updated Oct 23, 2026